Fabtech Technologies

Fabtech Technologies' board on June 25, 2026 approved additional investments of up to ₹24 crore into its Sharjah-based wholly-owned subsidiary Fabtech Technologies LLC to strengthen EPC operations abroad. The board also cleared a ₹2.49 crore equity investment into FT Institutions Private Limited, a domestic pharma and healthcare focused subsidiary. The overseas subsidiary remains non-revenue generating, while FT Institutions reported revenue of ₹12.61 crore and a net profit of ₹0.38 crore for FY26. Both transactions are cash subscriptions at par and are expected to be completed within a year, subject to regulatory approvals. Separately, the board noted the completion of independent director Shyam Nagorao Khante’s tenure effective that day, and reconstituted its audit, nomination and remuneration, and CSR committees from June 26.

Powered by Tijori

Fabtech Technologies has won a turnkey order worth roughly ₹31.23 crores from Botswana Vaccine Institute Limited to supply HVAC and Clean Room systems for a blending and filling project in Botswana. The contract covers design, supply, installation, testing, and commissioning, with a 14-month execution timeline. The international order bolsters Fabtech's order book and expands its footprint in the African market, complementing its existing Middle East and domestic operations.

Powered by Tijori

June 15 (Reuters) - Fabtech Technologies Ltd FABE.NS:

• FABTECH TECHNOLOGIES - SECURES ORDER FROM BOTSWANA VACCINE INSTITUTE FOR 312.3 MILLION RUPEES

Source text: ID:nNSE3g1vym

Further company coverage: FABE.NS

(([email protected];))

** Shares of Fabtech Technologies FABE.NS rise 12.6% to 182.8 rupees, their highest since Jan 19

** Pharma engineering firm's Q4 consol net profit rises about 46% Y/Y, aided by strong demand for its engineering services; rev up 17.5%

** Over 4.5 mln shares traded so far, about 7x 30-day avg

** Stock down 10.8% YTD

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

** Shares of Fabtech Technologies FABE.NS slip 8.4% to 149.50 rupees

** The medical equipment and supply company posts third-quarter consol net loss of 56.8 million rupees ($627,393) vs a profit of 204.6 million rupees in the year-ago period

** Third-quarter revenue down 39.8% Y/Y

** Trading vols over 2x the 30-day average at 1.1 million shares

** FABE stock down ~24% so far in 2026

($1 = 90.3740 Indian rupees)

(Reporting by Vijay Malkar)

(([email protected];))

** Shares of Fabtech Technologies FABE.NS drop to exchange-allowed maximum of 182.40 rupees in trading debut

** FABE valued at 8.11 bln rupees ($91.4 mln) as of 12:01 IST

** Stock opened at 192 rupees, 0.5% higher than IPO price of 191 rupees

** FABE provides turnkey engineering solutions for pharmaceuticals, biotech and healthcare companies

** Co's 2.3 bln rupee IPO, which was entirely an issue of new shares, was subscribed 2.03x

** Trading vols 4 mln shares so far

** Proceeds from IPO to be used for funding working capital requirements, pursuing inorganic growth through acquisitions, and other corporate purposes

($1 = 88.7170 Indian rupees)

(Reporting by Vijay Malkar)

(([email protected];))